Introduction
In recent years, screening cancer therapeutic drugs from natural products has become a focus in cancer prevention and treatment research. The efficacy of traditional Chinese medicines and their extracts in the treatment of diseases has been recognized, and more effective drugs for treating tumors are being identified. Brucea javanica is a shrub that mainly grows in Asia, particularly in southern China, and is used to treat a variety of diseases, such as malaria (1), amoebic dysentery (2) and tumors (3). Brusatol (BRU), an important component extracted from Brucea javanica (2), exerts a multitude of biological effects, including inhibiting the growth of tumor cells, reducing the reproduction of malaria parasites, reducing inflammation and resisting virus invasion (4). Clinical trials have demonstrated that BRU is a potential anticancer drug with potent cytotoxicity towards several types of cancer cells, including colorectal cancer (5), pancreatic cancer (6) and lung cancer (7). In addition, BRU can enhance the sensitivity of cancer cells to chemotherapeutic drugs by specifically blocking the expression of nuclear factor erythrocyte 2 related factor 2 (NRF2) (7,8). These findings suggest that BRU may be an effective antineoplastic drug and may be developed as a chemotherapeutic adjuvant for the treatment of a variety of tumors (9). Unfortunately, BRU is associated with several toxicities, including cardiac ischemia/reperfusion injury (10). It also reverses the therapeutic effects of other drugs, leading to aggravation of neuroinflammation and nerve injury (11), septicemic kidney injury (12), liver injury (13) and intestinal epithelial cell injury (14). These toxicities are attributed to the inhibition of NRF2. Furthermore, other studies have reported that BRU can affect the early development of mouse embryos and exerts toxic effects on mouse oocytes (15,16). However, the response rate to most chemotherapeutics in the treatment of human cancer remains low, and there is an urgent need for developing new and safe therapeutic agents.
Cancer is one of the most devastating diseases and constitutes a major threat to global public health and quality of life. Cancer is the second most fatal disease after cardiovascular disease in developed and developing countries (17). There were a reported 9.6 million deaths and 18.1 million new cancer cases worldwide in 2018 (18,19). Lung cancer is one of the most common malignant tumors and a leading cause of cancer-related mortality (20), whereas endometrial and ovarian cancers are the most common malignant tumors of the female reproductive system. The incidence of ovarian cancer is slightly lower compared with that of endometrial cancer (21). In the early stages of the three cancers mentioned above, the symptoms are not obvious; therefore, these cancers are often diagnosed after extensive metastasis has occurred, and the treatment methods are ineffective, resulting in poor prognosis (22-24). Therefore, with the rapid increase of cancer cases worldwide, it is crucial to develop and screen potential anticancer drugs (25). However, the currently available anticancer drugs can cause serious side effects and complications. Therefore, there is an urgent need for effective and low-toxicity treatment methods, and for innovative anticancer strategies in order to reduce the mortality of patients with malignant tumors and improve their quality of life (26).
Targeted drug therapy using nanoparticles (NPs) is a new method of cancer treatment, which greatly improves the therapeutic effect of several existing drugs (27,28). The effectiveness of NPs and selective killing of cancer cells have been confirmed in several studies (29-31). A major study reported that glycosaminoglycan-placental chondroitin sulfate A (plCSA) is widely expressed in human tumors, with absent-to-low expression in normal tissues other than the placenta (32). In addition, our previous research demonstrated that plCSA-binding peptide (plCSA-BP) lipid polymer NPs could rapidly bind to choriocarcinoma cells and notably enhance the anticancer activity of doxorubicin in vivo (33). Therefore, the use of plCSA-targeting lipid polymer NPs to treat human cancers is a newly recognized tool for delivering drugs to cancer cells, while minimizing the risk of injury to normal cells.
In the present study, plCSA-targeted lipid polymer NPs that encapsulated BRU were used to validate its efficiency and targeting of various tumors in vitro, such as lung, endometrial and ovarian cancer. The uptake of plCSAcoumarin 6 NPs (CNPs) by tumor cells was compared to that of other types of NPs, and it was investigated whether plCSA-brusatol-loaded NPs (BNPs) effectively promoted the apoptosis of cancer cells and inhibited their proliferation, invasion and migration through regulating the B-cell CLL/lymphoma 2 (BCL2), BCL2-associated X protein (BAX), cleaved caspase-3, matrix metalloproteinase (MMP)-2 and MMP-9 pathways.
Materials and methods
Experimental materials
Soybean lecithin and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy (polyethylene glycol)-2000] (DSPEPEG-COOH) were purchased from Avanti Polar Lipids, Inc. Poly(DL-lactic-co-glycolic acid) (50:50) (PLGA), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), and N-hydroxysuccinimide (NHS), were purchased from Sigma-Aldrich; Merck KGaA. The plCSA-binding peptide (EDV KDI NFD TKE KFL AGC LIV SFH EGKC) and the scrambled peptide (SCR; EVD NDK KLG LVF EKD KIF TEF ACI SHC G) were synthesized by ChinaPeptides Co., Ltd. and Shanghai GL Biochem Co. Ltd. BRU was purchased from Absin. Transwell 24-well 8.0-µm pore transparent plates were purchased from BD Biosciences. Matrigel was purchased from Corning, Inc. The Cell Counting Kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies, Inc. The anti-Bcl-2-associated X protein (BAX) (cat. no. 2774), anti-B-cell lymphoma (BCL)-2 (cat. no. 2875), anti -cleaved caspase-3 (cat. no. 9661), anti-MMP-2 (cat. no. 40994), anti-MMP-9 (cat. no. 13667) and anti-GAPDH (cat. no. 5174) were purchased from Cell Signaling Technology, Inc. All other materials were obtained from Sigma-Aldrich; Merck KGaA, unless otherwise specified.
BNPs or CNPs were synthesized using a single-step sonication method using PLGA, soybean lecithin, BRU or coumarin 6, and DSPE-PEG-COOH. PLGA was dissolved in acetonitrile, and soybean lecithin and DSPE-PEG-COOH were dissolved in 4% ethanol solution. BRU was dissolved in DMSO at a concentration of 10 mg/ml and coumarin 6 was dissolved in DMSO at a concentration of 1 mg/ml. To prepare BNPs, 750 µg of BRU, 90 µg of soybean lecithin and 210 µg of DSPE-PEGCOOH were added into 3 ml of 4% ethanol aqueous solution, and then an ultrasonic processor (VCX 130; Sonics & Materials) was used to treat the solution. The frequency of the ultrasonic processor was 20 kHz, the power was 30 W, and the time interval was 5 min. The BNPs were then centrifuged (34,000 × g) for 30 min at 4°C (Optima™ MAX-XP; Beckman Coulter, Inc.). After centrifugation, the supernatant was removed, and the precipitate was resuspended in 1 ml of PBS (pH 7.4). The NPs were purified by washing in PBS through an Amicon Ultra-4 centrifugal filter (molecular weight cut-off, 10 kDa; EMD Millipore), and these steps were repeated three times. CNPs were prepared using the same method.
Conjugation of plCSA-BP or SCR to the NPs
EDC/NHS technology was used to bind peptides to the surface of the NPs. In brief, to bind plCSA-BP or SCR to the BNP surface, activation buffer, EDC and NHS were added, and the molar ratio of DSPE-PEG-COOH:NHS:EDC was 1:2:2 to activate the carboxyl groups. The EDC/NHS solution and BNPs were mixed at room temperature for 30 min, and then plCSA-BP or SCR were added. The mixture was stirred at room temperature for 1-2 h, and then stored overnight at 4°C. To remove the unbound peptide, the product was reconstituted and purified as described above. PlCSA-BP and SCR-conjugated CNPs were prepared using the same method.
Encapsulation efficiency (EE) and drug loading efficiency (LE) of BRU in the NPs
The EE and LE of BRU in the NPs were determined as described below. First, the following steps were used to produce a standard curve: BRU was dissolved in DMSO at concentrations of 1, 5, 10, 20, 30, 50 and 80 µg/ml. The absorption of the BRU solution at 280 nm was measured using an ultraviolet visible (UV-vis) spectrophotometer (f900, Edinburgh Instruments Ltd.), and then the standard curve was generated according to the concentration of BRU. Subsequently, 25 µl of NPs were diluted with 500 µl of ultra-pure water, and the absorption at 280 nm was measured using the UV-vis spectrophotometer. The drug concentration was calculated using the standard curve. The EE and LE were calculated as follows: EE=(amount of drug in NPs/amount of added drug) ×100%; and LE=(amount of drug in NPs/total weight of materials) ×100%.
Cell culture and treatment
The human ovarian adenocarcinoma cell line SKOV3 was obtained from Wuhan Boster Biological Technology, Ltd. The human lung epithelial cell adenocarcinoma cell line A549 was obtained from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences. The human endometrial adenocarcinoma cell line HEC-1-A, the normal human ovarian epithelial cell line IOSE80, human endometrial stromal cells (hESCs), and the normal human lung epithelial cells BEAS-2B, were purchased from BeNa Culture Collection. The A549 cells were grown in DMEM; the SKOV3 and HEC-1-A cell were maintained in McCoy's 5A medium; IOSE80 and BEAS-2B cells were cultured in RPMI-1640 medium; and hESCs were cultured in DMEM/F12 supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.), 100 µg/ml streptomycin and 100 U/ml penicillin G. Apart from the different media, all the cell culture conditions were the same as mentioned above. All cells were placed in a cell culture chamber with 5% CO2 at 37°C with sufficient saturated humidity.
BRU does not emit light; therefore, coumarin 6 was used instead of BRU to treat cells, in order to observe the rate of uptake of the NPs. First, cells were grown to 70-80% confluence and treated with free coumarin 6, CNPs, SCR-CNPs, or the plCSA-CNPs, in 24-well plates for 1 h at 4°C. The cells were washed with PBS to remove unconjugated coumarin 6 or NPs, and incubated for 30 min at 37°C. Only surface-bound NPs were allowed to internalize. The cells in each group were then fixed at room temperature for 15 min with 4% paraformaldehyde, stained with 2-(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI) for 10 min at room temperature, washed with PBS three times, and fixed at room temperature for 15 min with 4% paraformaldehyde. Finally, the cells of each group were observed under an inverted fluorescence microscope (IX73; Olympus Corporation) at a magnification of ×200. Four visual fields were randomly selected to calculate the fluorescence intensity.
Detection of in vitro cell viability using the CCK-8 assay
The CCK-8 method was used to detect the effect of different treatments on the viability of tumor cells (SKOV3, HEC-1-A and A549) and normal cells (IOSE80, hESCs and BEAS-2B). Cells in the logarithmic growth phase were digested with trypsin. Thereafter, the cell concentration was adjusted to 10,000 cells/ml and the cells were inoculated into a 96-well plate at a density of 100 µl/well. Subsequently, the free BRU, BNPs, SCR BNPs, or plCSA-BNPs at concentrations of 0, 0.2, 0.4, 0.6, 0.8, 1 and 2 µg/ml were added to the culture cells for drug intervention. Each concentration was set with six replicate wells. The plates were cultured at 37°C and 5% CO2. After 48 h of cell culture, 20 µl of CCK-8 solution was added to each well. The cells were incubated for 1 h before the reaction was terminated and detected using an automatic enzyme marker.
Apoptosis assay using PE Annexin V staining
The cellular apoptosis rate was determined using a PE Annexin V Apoptosis Detection kit I (BD Biosciences) according to the manufacturer's protocol. Briefly, tumor cells (SKOV3, HEC-1-A and A549) and normal cells (IOSE80, hESCs and BEAS-2B) were seeded into 6-well plates and treated with free BRU or plCSA-BNPs for 24 h. On the following day, the cells were harvested, washed twice with cold PBS, resuspended in 500 µl of binding buffer, and stained with 5 µl 7-AAD and 5 µl PE Annexin V for 15 min at room temperature (25°C) in the dark. Fluorescence signals from at least 10,000 cells were analyzed immediately using a FACSCalibur flow cytometer (BD Biosciences). Dot plots and histograms were analyzed using FlowJo software, v7.6.1 (FlowJo, LLC).
Wound healing and Transwell invasion assays
For the cell invasion assay, pure Matrigel was diluted with PBS at a ratio of 1:20, and then the diluted Matrigel was added to the upper surface of the Transwell filter and placed in the incubator at 37°C for 2 h. Subsequently, cells treated with free BRU or plCSA-BNPs for 24 h were inoculated into the upper chamber in 200 µl of culture medium without FBS, and 600 µl of culture medium with 10% FBS was added into the plate. After 2 days of incubation, the cells attached to the upper surface of the filter were removed with cotton swabs, and the cells remaining on the lower surface were fixed with 4% paraformaldehyde for 15 min at room temperature and stained with 0.5% crystal violet solution for 10 min at room temperature. Subsequently, cells invading the lower surface were counted in five random fields (magnification, ×100) under an inverted fluorescence microscope (IX73; Olympus Corporation). For the migration assay, cells were seeded into 6-well plates until ~100% confluent, and the confluent cell layer on an agar plate was scratched with a 200-µl pipette tip. The cells were then washed with PBS and treated with free BRU or plCSA-BNPs, then incubated in serum-free medium. The degree of wound closure in each case was imaged and plotted at 0 and 24 h.
Western blotting
Free BRU or plCSA-BNPs were added to cells in the logarithmic growth phase and incubated at 37°C for 24 h. The cells were lysed by grinding on ice in RIPA buffer at 4°C for 30 min. The lysate was centrifuged at 12,000 × g at 4°C for 10 min. One part of the supernatant was used to detect the protein concentration using a BCA Protein Assay kit (Beyotime Institute of Biotechnology). The other part of the supernatant was added 4X sample buffer, boiled for denaturation, and then subjected to SDS-PAGE with a 4% concentrating gel and a 10% separation gel. Subsequently, the separated proteins were transferred onto PVDF membranes (EMD Millipore). The membranes were then blocked with 5% non-fat dry milk in Tris-buffered saline with 0.1% Tween 20 (TBST) for 1.5 h and incubated with the primary antibodies (BAX, 1:1,000 dilution; BCL2 , 1:1,000 dilution; cleaved caspase-3, 1:1,000 dilution; MMP-2, 1:1,000 dilution; MMP-9, 1:1,000 dilution; and GAPDH, 1:1,000 dilution) at 4°C overnight. After washing with TBST three times, the membranes were further incubated with the secondary antibody (cat. no. SA00001-2; 1:5,000 dilution; goat anti-rabbit; ProteinTech Group, Inc.) for 1 h at room temperature, and the color was developed using ECL chemiluminescent solution (Beyotime Institute of Biotechnology). Finally, images were acquired and the optical density value of the immunoreactive protein bands were analyzed using Image J software, version 1.51j8 (Media Cybernetics, Inc.). Loading was normalized using GAPDH.
Statistical analysis
All experimental data are expressed as the mean ± standard deviation of at least three independent experiments. GraphPad Prism 7.0 (GraphPad Software, Inc.) was used for the statistical analysis. One-way ANOVA followed by Tukey's post hoc test and two-way ANOVA followed by Bonferroni's post hoc test was used to analyze the differences among groups. P<0.05 was considered to indicate statistically significant differences.
Results
Characterization of NPs
The drug EE and LE of the NPs are crucial to ensure a successful drug delivery system. The EE and LE of BRU in the NPs were calculated by constructing standard curves. The EEs of BRU for the BNPs, SCR-BNPs and plCSA-BNPs were 40.3±1.67, 38.8±1.83 and 39.5±1.94%, respectively. The LEs of BRU for the BNPs, SCR-BNPs and plCSA-BNPs were 6.2±0.74, 5.3±0.56 and 5.1±0.42%, respectively. These data indicate that the extent of drug loading and drug encapsulation was maintained after plCSA-BP decoration of the NPs.
In vitro cellular uptake assay of the NPs
In order to test whether the combination of plCSA-BP with nanocarriers could increase the absorption of NPs by the tumors, the SKOV3, HEC-1-A and A549 cell lines were cultured with different NPs. Fluorescence microscopy demonstrated that cancer cells treated with plCSA-CNPs had a higher fluorescence intensity compared with that of the other treatments. Moreover, in SKOV3, HEC-1-A and A549 cells, the NP uptake of the targeted preparation into the cells was >9 times that of the non-targeted control (P<0.0001; Fig. 1A-F). These results suggest that the plCSA-targeting agent-absorbed NPs had a better targeting efficiency compared with the non-targeted controls. In addition, the combination with SCR did not lead to enhanced uptake of NPs by the different cancer cells, indicating the specific role of plCSA in the uptake by tumor cells.
Toxicity of BRU and plCSA-BNPs toward normal cells
In order to evaluate the effect of BRU and plCSA-BNPs on normal cells, the CCK-8 method was used to determine the cytotoxicity of different NPs after 24 h. The results revealed that 0-2 µg/ml of BRU could significantly inhibit the growth of normal cells (IOSE80, hESCs and BEAS-2B), and the cytotoxicity increased with increasing BRU concentration. However, the toxicity of plCSA-BNPs toward normal cell lines was significantly lower compared with that of free BRU (Fig. 2A). The P-values of IOSE80 cells treated with plCSA-BNPs at 0.2, 0.4, 0.6, 0.8, 1 and 2 µg/ml compared with that of cells treated with free BRU were 0.0163, 0.0003, <0.0001, <0.0001, <0.0001 and <0.0001, respectively. The P-values of hESCs treated with plCSA-BNPs at 0.2, 0.4, 0.6, 0.8, 1 and 2 µg/ml compared with that of cells treated with free BRU were 0.0243, 0.0002, <0.0001, <0.0001, <0.0001 and <0.0001, respectively. The P-values of BEAS-2B cells treated with plCSA-BNPs at 0.2, 0.4, 0.6, 0.8, 1 and 2 µg/ml compared with that of cells treated with free BRU were 0.0422, 0.0153, 0.0005, <0.0001, <0.0001 and <0.0001, respectively. According to the IC50 values of these NPs and free BRU, we analyzed the advantages of the targeting NPs. The IC50 of plCSA-BNPs (9.767 µg/ml) in IOSE80 cells was significantly higher compared with that of free BRU (1.863 µg/ml). The IC50 of plCSA-BNPs (5.492 µg/ml) in hESCs was significantly higher compared with that of free BRU (1.8243 µg/ml). The IC50 of plCSA-BNPs (8.262 µg/ml) in BEAS-2B cells was significantly higher compared with that of free BRU (1.938 µg/ml). These results demonstrated that BNPs combined with plCSA-BP effectively reduced the cytotoxicity compared with that of free BRU (P<0.05; Fig. 2A). Moreover, to further verify these findings, the ratios of apoptotic cells were detected using flow cytometry. The apoptosis rates of IOSE80, hESCs and BEAS-2B cells treated with plCSA-BNPs were 7.000±0.289, 6.033±0.145 and 6.133±0.240%, respectively, while those of IOSE80, hESCs and BEAS-2B cells treated with free BRU were 11.500±0.252, 11.267±0.371 and 11.067±0.521%, respectively, which demonstrated that the apoptosis rates in cells treated with BRU were 1.6 (P<0.0001), 1.8 (P<0.0001) and 1.8 (P=0.0002) times higher compared with those in cells treated with free plCSA-BNPs (Fig. 2B). The results indicated that free BRU increased the apoptosis of normal cells, whereas plCSA-BP could reduce this effect. These in vitro results suggested that plCSA-BNPs could reduce cytotoxicity compared with that of free BRU.
plCSA-BNPs strongly inhibits tumor cell growth
To confirm the antitumor activity of BRU and plCSA-BNPs, the CCK-8 assay was used to evaluate cell viability after 24 h of treatment with different NPs. The results demonstrated that BRU significantly inhibited the activity of the three types of cancer cells, and both targeted (plCSA-BNPs) and non-targeted (BNPs and SCR-BNPs) NPs exhibited dose-dependent cytotoxicity. When the dosage was 0.2 -2 µg/ml, the killing effect of plCSA-BNPs on SKOV3, HEC-1-A and A549 cells was stronger compared with that of BNPs and SCR-BNPs (Fig. 3A). The P-values of SKOV3 cells treated with plCSA-BNPs at 0.2, 0.4, 0.6, 0.8, 1 and 2 µg/ml compared with that of cells treated with free BRU were 0.0173, <0.0001, <0.0001, <0.0001, <0.0001 and <0.0001, respectively. The P-values of HEC-1-A cells treated with plCSA-BNPs at 0.2, 0.4, 0.6, 0.8, 1 and 2 µg/ml compared with that of cells treated with free BRU were <0.0001, <0.0001, <0.0001, 0.0004, <0.0001 and <0.0001, respectively. The P-values of A549 cells treated with plCSA-BNPs at 0.2, 0.4, 0.6, 0.8, 1 and 2 µg/ml compared with that of cells treated with free BRU were 0.0055, <0.0001, <0.0001, 0.002, <0.0001 and <0.0001, respectively. According to the IC50 values of these NPs and free BRU, the advantages of the targeting NPs were analyzed. The IC50 of plCSA-BNPs (0.5734 µg/ml) in SKOV3 cells was significantly lower compared with that of free BRU (1.832 µg/ml). The IC50 of plCSA-BNPs (0.2378 µg/ml) in HEC-1-A cells was significantly lower compared with that of free BRU (0.975 µg/ml). The IC50 of plCSA-BNPs (0.7084 µg/ml) in A549 cells was significantly lower compared with that of free BRU (2.364 µg/ml). These results suggested that conjugating the BNPs with plCSA-BP effectively improved the growth inhibition of tumor cells compared with that of free BRU (P<0.05; Fig. 3A). Moreover, to further verify the findings mentioned above, the ratios of apoptotic cells were detected using flow cytometry. The apoptosis rates of SKOV3, HEC-1-A and A549 cells treated with plCSA-BNPs were 18.867±0.593, 35.533±0.742 and 15.60±0.702%, respectively, while those of SKOV3, HEC-1-A and A549 cells treated with free BRU were 13.933±0.581, 12.033±0.578 and 10.00±0.577%, respectively, which demonstrated that the apoptosis rates in cells treated with plCSA-BNPs were 1.3 (P=0.0012), 2.9 (P<0.0001) and 1.5 (P=0.0009) times higher compared with those treated with free BRU (Fig. 3B). These results demonstrated that free BRU increased cell apoptosis, whereas plCSA-BP further enhanced this effect. These in vitro results suggested that plCSA-BNPs may be a suitable candidate for cancer therapy.
plCSA-BNPs strongly inhibit tumor cell invasion
Transwell experiments were used to compare the effects of free BRU and plCSA-BNPs on cell invasion. In SKOV3, HEC-1-A and A549 cells, the cell invasion inhibition rates of the plCSA-BNPs group were 6.2 (P=0.0007), 2.6 (P=0.0429) and 9.6 (P<0.0001) times higher compared with those of the BRU group, respectively. These results demonstrated that plCSA-BNPs significantly inhibited cell invasion (Fig. 4A-C).
plCSA-BNPs strongly inhibit tumor cell migration
Wound healing assays were performed to compare the effects of plCSA-BNPs and free BRU on cell migration. In SKOV3, HEC-1-A and A549 cells, the cell migration inhibition rates of the plCSA-BNPs group were 3 (P<0.0001), 3.6 (P<0.0001) and 5.9 (P<0.0001) times higher compared with those of the BRU group, respectively. These results demonstrated that plCSA-BNPs significantly inhibited cell migration compared with the control group (Fig. 5A-C).
plCSA-BNPs inhibit cancer cell proliferation, invasion and migration by regulating the BCL2/BAX, cleaved caspase-3 and MMP pathways
To explore the molecular mechanisms underlying the effects of BRU on cancer cells, the SKOV3 cell line was selected, treated with BRU and the different NPs, and then western blotting was used to study the levels of apoptosis-related proteins, such as BCL2, BAX and cleaved caspase-3, and migration- and invasion-related proteins, such as MMP-2 and MMP-9. The levels of the apoptosis-related proteins BCL2, BAX and cleaved caspase-3, as well as those of the migration- and invasion-related proteins MMP-2 and MMP-9 are shown in Fig. 6B. Treatment with free BRU resulted in significant downregulation of BCL2, MMP-2 and MMP-9 levels, and upregulation of BAX and cleaved caspase-3 levels, compared with those in the control group. In addition, the same expression trends were observed following plCSA-BNPs treatment for 24 h; however, the protein levels were altered to a greater degree compared with those after free BRU treatment. For BCL2, BAX, cleaved caspase-3, MMP-2 and MMP-9, the changes the protein levels in the plCSA-BNPs group were 2 (P=0.0028), 2.2 (P=0.0192), 2 (P=0.0185), 3.5 (P<0.0001), and 2 (P<0.0001) times greater compared with those in the BRU group, respectively. These results indicated that BRU promoted cancer cell death by inhibiting cancer cell proliferation, invasion and migration, whereas encapsulating BRU as plCSA-BNPs enhanced these effects.
Discussion
BRU has notable anticancer activity and may improve disease outcomes in various cancers (34,35). However, BRU is associated with a number of toxic adverse effects (10-16), which may limit its application in the clinical setting. Nanocarriers are promising systems for the effective treatment of cancer (36,37). As mentioned above, glycosaminoglycan plCSA is specifically expressed in most cancer cells and placental trophoblasts. Therefore, plCSA-NPs may be used in targeted therapy of human tumor cells. Thus, it was hypothesized that encapsulating BRU in plCSA-modified NPs would prevent its inherent side effects (36). In the present study, plCSA-BP-conjugated lipid-polymer NPs loaded with BRU (plCSA-BNPs) were synthesized. We observed that the uptake of plCSA-BP modified NPs by cancer cells was markedly higher compared with that of other types of NPs. Three different cancer cell lines were treated with free BRU, BNPs, SCR-BNPs or plCSA-BNPs. The results demonstrated that plCSA-BNPs promoted the apoptosis of cancer cells more effectively, and inhibited the proliferation, invasion and migration of cancer cells by regulating the BCL2, BAX, cleaved caspase-3, MMP-2 and MMP-9 pathways. The results of the present study will hopefully improve our understanding of the successful application of plCSA-BP modified NPs and provide an effective tool for targeted drug delivery to cancer cells. These plCSA targeting lipid polymer NPs may be used to deliver drugs that target most human cancers, thereby representing a breakthrough in the targeted therapy of cancer and supporting the development of new drug targeting methods for traditional Chinese medicines.
The EE and LE of drugs in NPs are crucial for their success as drug delivery systems (33). It was reported that the particles were more stable when the drug loading levels were lower (38). Furthermore, the drug loading amount is a key factor for the drug EE (38). Therefore, in the present study, loading of small drug amounts was performed to ensure that the prepared NPs were more stable.
Previous studies demonstrated that tumor cells display good uptake of liposome polymer NPs (38,39). For example, Chu et al proved that PEGPE/PLGA NPs exhibited higher drug loading, less sudden release, good serum stability and higher cell uptake compared with traditional PLGA NPs (40). The results of the present study demonstrated that tumor cells were also capable of taking up plCSA-CNPs, which is consistent with previous research results (39-41). Our data suggested that plCSA-BNPs efficiently delivered drugs into tumor cells to eliminate them.
BRU has been shown to modulate the apoptosis, migration and invasion of human cancer cells (42), indicating its potential role in cancer metastasis. Therefore, CCK-8 and cell apoptosis assays were used to study the effects of BRU and different NPs on tumor cells and normal cells. The effects of BRU and different NPs on tumor cells were studied using migration and Transwell invasion assays. The cytotoxicity of targeted (plCSA-BNPs) and non-targeted (BNPs and SCR-BNPs) NPs against normal cells was less prominent compared with that of free BRU, while BRU exerted a significant inhibitory effect on the tumor cells, and both targeted (plCSA-BNPs) and non-targeted (BNPs and SCR-BNPs) NPs exhibited dose-dependent cytotoxicity. When the drug concentration was 0.2-2 µg/ml, the killing effect of plCSA-BNPs on SKOV3, HEC-1-A and A549 cells was stronger compared with that of free BRU, BNPs and SCR-BNPs, suggesting that the combination of BNPs and plCSA-BP significantly enhanced the growth inhibitory and pro-apoptotic effect of BRU on tumor cells. Moreover, plCSA-BNPs could significantly reduce the killing effect of BRU on normal cells. Thus, the NPs maintained the antitumor activity of BRU and reduced its toxicity toward non-tumor cells. The process of tumorigenesis and development is extremely complex. In the present study, one cell line was selected, treated with BRU and the different NPs, and western blotting was further employed to examine the levels of apoptosis-related proteins and migration- and invasion-related proteins. Apoptosis may occur through two pathways: Extrinsic and intrinsic. However, there is now evidence that these two pathways are interrelated, with molecules in one pathway affecting the other (43). There is an additional pathway that involves T-cell mediated cytotoxicity and perforingranzyme-dependent killing of cells. This perforin/granzyme pathway can induce apoptosis via either granzyme B or granzyme A. The extrinsic, intrinsic and granzyme B pathways converge on the same terminal, or execution, pathway. This pathway is initiated by the cleavage of caspase-3 (44), and the direct activation of caspase-3 is essential for granzyme B-induced cell killing (45). It has been reported that members of the BCL2 family regulate the process of apoptosis, including anti-apoptotic and pro-apoptotic transcription factors, such as BCL2 and BAX, respectively. The activity of BAX leads to cytochrome c release to promote apoptosis. By contrast, as an anti-apoptotic protein, BCL2 can prevent apoptosis-related death (46). BRU may also inhibit invasion, migration and epithelial-to-mesenchymal transition (42). The interaction between apoptotic and anti-apoptotic proteins determines cell survival. Members of the MMP family are associated with cell migration and invasion. MMP-2 and MMP-9 are the two most extensively investigated members of the MMP family (47). In accordance with previous studies, we found that among the three groups, the levels of cleaved caspase-3 were significantly higher in the plCSA-BNPs group. Therefore, plCSA-BNPs significantly increased the transformation of the inactive procaspase-3 to active cleaved caspase-3, which is the main inducer of apoptosis. plCSA-BNPs promoted the levels of pro-apoptotic factors by significantly increasing the expression of pro-apoptotic BAX. A slight reduction in the levels of the anti-apoptotic BCL2 protein was also observed. In addition, the plCSA-BNPs strongly inhibited the expression of migration- and invasion-related proteins, such as MMP-2 and MMP-9. These results demonstrated that BRU, delivered via plCSA-modified NPs, may play a key role in promoting cancer cell apoptosis and inhibiting invasion and migration via regulation of important related proteins.
In conclusion, as a drug delivery system, plCSA-BP-conjugated lipid polymer NPs loaded with BRU exerted a notable antitumor effect in vitro, which could provide the basis for the development of new anticancer drug delivery systems.